NovoCure (NVCR) Capital Expenditures (2014 - 2026)

NovoCure's Capital Expenditures history runs 13 years deep, the most recent figure standing at $5.2 million for Q1 2026.

• In Q1 2026, Capital Expenditures fell 51.45% year-over-year to $5.2 million; the TTM figure through Mar 2026 stood at $21.2 million (down 49.17% YoY), while the FY2025 annual figure was $26.6 million, down 37.82% from the prior year.
• Capital Expenditures came in at $5.2 million for Q1 2026 at NovoCure, up from $4.9 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $11.8 million in Q1 2024 to a low of $4.1 million in Q2 2022.
• A 5-year average of $7.2 million and a median of $6.4 million in 2022 frame the typical range for Capital Expenditures.
• Across the five-year window, Capital Expenditures slumped 54.95% in 2022 and surged 93.56% in 2024, its largest moves.
• NovoCure's Capital Expenditures stood at $6.4 million in 2022, then advanced by 6.06% to $6.8 million in 2023, then jumped by 31.1% to $8.9 million in 2024, then plunged by 45.25% to $4.9 million in 2025, then climbed by 5.23% to $5.2 million in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $5.2 million, $4.9 million, and $5.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison